# A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects

> **NCT02688387** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 112 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose
- **DRUG:** Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)

## Key facts

- **NCT ID:** NCT02688387
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-18
- **Primary completion:** 2017-08-04
- **Final completion:** 2017-08-04
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2019-01-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02688387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02688387, "A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02688387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*